Three significant customers accounted for 53% of 2025 revenue, creating customer concentration risk.

IonQ’s Q1 2026 net income was dominated by a $1.058 billion non-operating warrant fair-value gain.

IonQ used $151.0 million of operating cash in Q1 2026, contradicting any simple reading of GAAP net income as cash generation.

IonQ’s remaining performance obligations included both funded and unfunded firm orders, so backlog is not all appropriated cash-backed demand.

Oxford Ionics revenue after acquisition was not material, so the largest 2025 acquisition did not yet validate revenue traction.

IonQ’s pending SkyWater acquisition would require about $1.0 billion of cash, materially reducing the cash runway if completed.

IonQ issued 16.0 million ATM shares in 2025 for $358.3 million net, showing willingness to dilute into market strength.

IonQ’s October 2025 offering raised $1.977 billion net and included 43.0 million Series B private warrants, a major capital-structure overhang.

IonQ’s July 2025 offering raised $977.2 million net and included 36.0 million Series A private warrants.

IonQ had 79.1 million Series A and B private warrants outstanding at March 31, 2026.

IonQ’s outstanding common shares rose to 373.2 million by March 31, 2026 from 362.6 million at year-end 2025.

IonQ says Q1 2026 adjusted EBITDA loss was $96.8 million, reinforcing that operations remain loss-making despite revenue growth.

IonQ’s 2025 acquisition purchase price allocation was still preliminary at March 31, 2026, leaving accounting-estimate risk.

IonQ recognized $5.3 million of Q1 2026 revenue from commercial contracts entered alongside its investment agreements, a revenue-quality item to verify.

IonQ’s supplier commitments included a $40.9 million short-term supplier purchase commitment related to quantum chip development.

IonQ’s filing acknowledges trapped-ion gate speeds are widely believed to be slow, a direct technical bear point.

IonQ’s 2025 acquisitions added $2.659 billion of purchase price, mostly stock consideration, increasing integration and dilution complexity.

IonQ’s board can issue preferred stock without further stockholder action, an anti-takeover/control provision.

IonQ’s risk factors say it recently experienced significant top-management turnover, a governance tell to track.

John W. Raymond adopted a 10b5-1 plan in March 2026 for potential sales of up to 18,253 shares.

The latest Form 4 cluster includes director sales under 10b5-1 plans and annual RSU grants, not open-market insider buying.

IonQ faces trapped-ion competitors including Quantinuum and Alpine Quantum Technologies, so the architecture is not exclusive to IonQ.

IonQ says competitors may achieve breakthroughs that render its systems obsolete or inferior.

IonQ expects significant losses and higher operating expenses for the foreseeable future, a direct valuation risk for a premium multiple.

Government contracts expose IonQ to early termination, audits, investigations, sanctions and penalties.

IonQ says it has not produced a scalable quantum computer, making commercial quantum advantage a core kill-switch.

IonQ says tariffs and evolving trade policy may increase operating costs and supply-chain pressure.

IonQ’s satellite operations depend on regulatory approvals, a risk added by its platform expansion beyond core quantum computing.

Compared with the prior 10-K, IonQ’s 2025 risk summary newly emphasized acquisitions including SkyWater and recent top-management turnover.

IonQ’s short-seller risk factor acknowledges short reports have been published about the company and can trigger volatility or regulatory scrutiny.

The FTC issued a Second Request on the SkyWater merger, making regulatory clearance a live catalyst and risk.

IonQ’s Q1 2026 press release says the SkyWater commercial relationship costs were expected to continue until regulatory approval and close.